Univar Solutions Expands Pharmaceutical Ingredients Portfolio Through New Distribution Agreement with SI Group
Univar Solutions announced a distribution agreement with SI Group on February 14, 2023, aimed at enhancing the Ibuprofen product market in Brazil. This partnership will enable Brazilian pharmaceutical manufacturers access to a robust portfolio of specialty ingredients, addressing the increased demand for over-the-counter analgesics. Univar Solutions' state-of-the-art Solution Center in São Paulo will support customers in formulating advanced pharmaceutical solutions. The collaboration emphasizes innovative technologies to improve time to market and sustainability, positioning Univar Solutions as a key player in the pharmaceutical ingredients sector.
- Distribution agreement with SI Group enhances Ibuprofen market position in Brazil.
- Access to a robust portfolio of innovative specialty ingredients addresses increased market demand.
- Strategic partnership supports improved time to market for pharmaceutical manufacturers.
- None.
Strategic partnership aims to support significant growth of the Ibuprofen product market in Brazil and is backed by Univar Solutions' state-of-the-art Solution Center in São Paulo, Brazil
SÃO PAULO, Feb. 14, 2023 /PRNewswire/ -- Univar Solutions Brasil Ltda., a subsidiary of Univar Solutions Inc. (NYSE: UNVR) ("Univar Solutions" or "the Company"), a leading global solutions provider to users of specialty ingredients and chemicals, today announced a distribution agreement with SI Group for Ibuprofen, an active pharmaceutical ingredient (API) used to produce ibuprofen drugs for the pharmaceutical market.
"Our strategic relationship with SI Group provides customers in Brazil access to a robust portfolio of innovative specialty ingredients and supply products in significant demand in the Brazilian market. We're proud to team up with a supplier who is also passionate about working at the intersection of science and technology to deliver products that help keep communities healthy and safe," said James Peterson, global vice president of pharmaceutical ingredients for Univar Solutions.
"Univar Solutions proudly serves pharmaceutical manufacturers and formulators focused on delivering advanced, science-based pharmaceutical solutions, offering the ingredients they seek for critically important health care products," said Jorge Buckup, president of Latin America for Univar Solutions. "Together with SI Group, we're better able to help customers formulate next-generation products, work to improve time to market, and achieve sustainable solutions through ingredients and innovations."
"SI Group is thrilled to grow our partnership with Univar Solutions, a global leader in ingredient and specialty distribution with deep expertise and a reliable, resilient network and supply chain solutions," said Cathryn D. Estes, senior director of pharmaceuticals and global distribution for SI Group. "Together, we can leverage our ingredients and services and bring our Brazilian customers the ingredients and products they need to grow and serve their markets."
With the recent increase in demand for over-the-counter analgesics, the addition of Ibuprofen to Univar Solutions' ingredients portfolio in Brazil will provide pharmaceutical manufacturers with an important source of supply. Combined with a team of industry experts, a global network of pharmaceutical compliant facilities, and Solution Centers staffed by technical experts, Univar Solutions offers pharmaceutical and biopharmaceutical customers and suppliers support for their pharmaceutical, ophthalmic, nutraceutical, biopharma, animal health and medical device applications.
For more information about Univar Solutions' global pharmaceutical ingredient solutions, visit univarsolutions.com/pharma.
About Univar Solutions
Univar Solutions (NYSE: UNVR) is a leading global specialty chemical and ingredient distributor representing a premier portfolio from the world's leading producers. With the industry's largest private transportation fleet and North American sales force, unparalleled logistics know-how, deep market and regulatory knowledge, world-class formulation and recipe development, and leading digital tools the company is well-positioned to offer tailored solutions and value-added services to a wide range of markets, industries, and applications. Univar Solutions is committed to helping customers and suppliers innovate and grow together. Learn more at univarsolutions.com.
About SI Group
SI Group is a global leader in the innovative technology of performance additives, process solutions, active pharmaceutical ingredients, and chemical intermediates. SI Group solutions are essential to enhancing the quality and performance of countless industrial and consumer goods within the plastics, rubber & adhesives, fuels & lubricants, oilfield, and pharmaceutical industries. SI Group's global manufacturing footprint includes 20 facilities on three continents, serving customers in 80 countries with approximately 2,000 employees worldwide. In 2021, SI Group received a gold award for corporate social responsibility by EcoVadis and is ranked among the top five percent of more than 50,000 worldwide companies. SI Group innovates and drives change to create value with a passion for safety, chemistry, sustainability, and extraordinary results. Learn more at www.siigroup.com.
Forward-Looking Statements
This press release includes certain statements relating to future events and our intentions, beliefs, expectations, and outlook for the future, which are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are subject to known and unknown risks and uncertainties, many of which may be beyond the Company's control. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from the expectations and assumptions. A detailed discussion of these factors and uncertainties is contained in the Company's filings with the Securities and Exchange Commission. Potential factors that could affect such forward-looking statements include, among others: general economic conditions, particularly fluctuations in industrial production and consumption and the timing and extent of economic downturns increased competitive pressures, including as a result of competitor consolidation; potential supply chain disruptions; significant changes in the pricing, demand and availability of chemicals; our indebtedness, the restrictions imposed by, and costs associated with, our debt instruments, and our ability to obtain additional financing; the broad spectrum of laws and regulations that we are subject to, including extensive environmental, health and safety laws and regulations and changes in tax laws; potential cybersecurity incidents, including security breaches; an inability to generate sufficient working capital; transportation related challenges, including increases in transportation and fuel costs, changes in our relationship with third party transportation providers, and ability to attract and retain qualified drivers; accidents, safety failures, environmental damage, product quality issues; delivery failures or hazards and risks related to our operations and the hazardous materials we handle, potential inability to obtain adequate insurance coverage; ongoing litigation, potential product liability claims and recalls, and other environmental, legal and regulatory risks; challenges associated with international operations; exposure to interest rate and currency fluctuations; possible impairment of goodwill and intangible assets; the ongoing and evolving COVID-19 pandemic, including impacts on the global economy, our employees, customers, vendors and suppliers, and our business, results of operation and financial condition; significant changes in the business strategies of producers or in the operations of our customers; an inability to integrate the business and systems of companies we acquire, including failure to realize the anticipated benefits of such acquisitions; negative developments affecting our pension plans and multi-employer pensions; labor disruptions associated with the unionized portion of our workforce; our ability to attract or retain a qualified and diverse workforce; our ability to execute on our strategies related to environmental, social, and governance matters, and achieve related expectations may be impacted as a result of evolving regulatory and other standards, processes, and assumptions, the pace of scientific and technological developments, increased costs and the availability of requisite financing and changes in carbon markets; and the other factors described in the Company's Annual Report on Form 10-K for the year ended December 31, 2021, as well as other filings with the Securities and Exchange Commission. We caution you that the forward-looking information presented in this press release is not a guarantee of future events or results, and that actual events or results may differ materially from those made in or suggested by the forward-looking information contained in this press release. In addition, forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "plan," "seek, "will," "expect," "intend," "estimate," "anticipate," "believe" or "continue" or the negative thereof or variations thereon or similar terminology. Any forward-looking information presented herein is made only as of the date of this press release and the Company does not undertake any obligation to update or revise any forward-looking information to reflect changes in assumptions, the occurrence of unanticipated events, or otherwise, except as required by law.
View original content to download multimedia:https://www.prnewswire.com/news-releases/univar-solutions-expands-pharmaceutical-ingredients-portfolio-through-new-distribution-agreement-with-si-group-301745983.html
SOURCE Univar Solutions Inc.
FAQ
What is the new partnership announced by Univar Solutions concerning Ibuprofen?
When was the distribution agreement for Ibuprofen announced by Univar Solutions?
How will the partnership with SI Group benefit Univar Solutions in Brazil?
What is the significance of the Solution Center in São Paulo for Univar Solutions?
What does the distribution agreement mean for pharmaceutical manufacturers in Brazil?
